Chronic disease by the numbers

January 2010
Canadian Nurse;Jan2010, Vol. 106 Issue 1, p10
Academic Journal
The article presents statistics on chronic diseases in Canada, including the number of estimated deaths in 2009 linked to chronic diseases, the portion of acute-care budgets spent on heart failure treatment in 2004 and 2005, and the costs of diabetes care.


Related Articles

  • Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't". Selman, Lucy; Harding, Richard; Beynon, Teresa; Hodson, Fiona; Coady, Elaine; Hazeldine, Caroline; Walton, Michael; Gibbs, Louise; Higginson, Irene J. // Heart;Aug2007, Vol. 93 Issue 8, p963 

    Background: Although chronic heart failure (CHF) has a high mortality rate and symptom burden, and clinical guidance stipulates palliative care intervention, there is a lack of evidence to guide clinical practice for patients approaching the end of life. Aims: (1) To formulate guidance and...

  • Value of eplerenone in HF according to age, gender. Everitt, Laura // PharmacoEconomics & Outcomes News;1/29/2005, Issue 470, p3 

    Presents the results of a study on the effects of eplerenone, an aldosterone antagonist, on the treatment of heart failure (HF) according to age and gender subgroups. Comparison of the mortality in the placebo group with the eplerenone group; Assessment of the healthcare resources used and...

  • Facts About Chronic Disease.  // PT in Motion;Oct2010, Vol. 2 Issue 9, p34 

    The article presents statistics on chronic disease such as its prevalence, mortality, and cost.

  • New recommendations urge 4-drug regimen for chronic heart failure. Pinkowish, Mary Desmond // Patient Care;4/15/1999, Vol. 33 Issue 7, p49 

    Summarizes the data supporting the use of a four-drug regimen for the treatment of chronic heart failure. Effectiveness of the combined use of digitalis, diuretics, beta-blockers and angiotensin-converting enzyme inhibitors; Reduction of mortality and morbidity associated with heart failure;...

  • Cost of HF care projected to double by 2030. Dellapena, Deb; Foster, Melissa // Cardiology Today;Jun2013, Vol. 16 Issue 6, p1 

    The article reports on the increase in the direct and indirect costs to treat heart failure (HF) by 2030, as projected by the American Heart Association (AHA).

  • Elevated HR in HFrEF linked to worse outcomes, higher cost.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 746 Issue 1, p20 

    The article reports on the study by A. D. DeVore and colleagues regarding the association of elevated heart rate (HR) among patients with heart failure with reduced ejection fraction (HFrEF) to increased medical costs and worsened 1-year outcomes.

  • Greater care continuity, better outcomes, lower costs.  // PharmacoEconomics & Outcomes News;Apr2014, Vol. 700 Issue 1, p7 

    The article discusses research being done on the costs of care for chronic disease, which references a study by P. S. Hussey et al published in the March 17, 2014 issue of "JAMA Internal Medicine."

  • The Conceptualization and Measurement of Comorbidity: A Review of the Interprofessional Discourse. Meghani, Salimah H.; Buck, Harleah G.; Dickson, Victoria Vaughan; Hammer, Marilyn J.; Rabelo-Silva, Eneida Rejane; Clark, Robyn; Naylor, Mary D. // Nursing Research & Practice;2013, p1 

    Background. Chronic medical conditions often occur in combination. Understanding underlying mechanisms causing diseases and their interactions may make it possible to address multiple complex conditions with single or consolidated treatment approaches and improve patients' health outcomes while...

  • The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. P, Berto; MP, Amato; P, Bellantonio; F, Bortolon; P, Cavalla; C, Florio; A, Lugaresi; E, Montanari; M, Rottoli; IL, Simone; M, Zaffaroni // Neurological Sciences;Dec2011, Vol. 32 Issue 6, p1035 

    Multiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurological symptoms that carry a substantial burden. Previous Italian studies appear outdated, and investigation on the burden of recently marketed drug treatments should provide further economic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics